Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.54 USD
Change Today +0.44 / 3.96%
Volume 590.8K
ADXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 1:11 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Snapshot

Open
$11.06
Previous Close
$11.10
Day High
$11.65
Day Low
$10.81
52 Week High
01/20/15 - $13.74
52 Week Low
04/15/14 - $2.46
Market Cap
307.7M
Average Volume 10 Days
732.2K
EPS TTM
$-0.97
Shares Outstanding
26.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVAXIS INC (ADXS)

Related News

No related news articles were found.

advaxis inc (ADXS) Related Businessweek News

No Related Businessweek News Found

advaxis inc (ADXS) Details

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

20 Employees
Last Reported Date: 01/6/15
Founded in 2002

advaxis inc (ADXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

advaxis inc (ADXS) Key Developments

Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM

Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Daniel J. O'Connor, Chief Executive Officer, President and Director.

Advaxis, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015

Advaxis, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Presentation Date & Speakers: Feb-23-2015, Robert G. Petit, Chief Scientific Officer and Executive Vice President.

Advaxis Appoints Mayo Pujols as Vice President of Manufacturing

Advaxis, Inc. announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy. In his role as Vice President, Manufacturing, Mr. Pujols will oversee production for the Company's multiple immunotherapy programs, which utilize bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), to actively suppress key components in the tumor microenvironment. Most recently, Mr. Pujols served as Executive Director, Technical Operations for Merck, Sharp & Dohme (MSD), the UK subsidiary of Merck & Co., Inc. As Executive Director, Technical Operations, Mr. Pujols led a team responsible for technical support and global supply of reliable, compliant, and cost competitive biologics, vaccines, and pharmaceuticals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $11.54 USD +0.44

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $21.23 USD -0.33
Eurocine Vaccines AB kr2.95 SEK -0.05
Genocea Biosciences Inc $8.55 USD -0.05
GenVec Inc $3.21 USD -0.05
Inovio Pharmaceuticals Inc $7.37 USD -0.19
View Industry Companies
 

Industry Analysis

ADXS

Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 207.0x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 232.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit www.advaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.